Thanks TechGuru. I agree 56% mortality reduction is a difficult target to hit. And if hit, no way the trial continues to run unless distribution and manufacturing are not ready to deliver product to hospitals.

I suspect that the mortality reduction will be more modest, maybe 20 or 30 percent. Not enough to end the trial. Just my guess.